Search | Clinical Trials Finder

ClinicalTrials.gov public records Last synced Sep 27, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–38 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Quetiapine-XR Clear all

Conditions: Borderline Personality Disorder
Interventions: quetiapine extended-release, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 45 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 3
States / cities: Iowa City, Iowa • Belmont, Massachusetts • Minneapolis, Minnesota

Conditions: Anxiety Disorders
Interventions: Quetiapine XR, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 66 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 14
States / cities: Fort Myers, Florida • Gainsville, Florida • Miami, Florida + 11 more

Conditions: Anxiety, Anxiety Disorders, Anxiety Neuroses, Anxiety States
Interventions: Placebo, quetiapine fumarate XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 53
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 50 more

Conditions: Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions: Brexpiprazole, Seroquel XR, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 2,182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 44
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more

Conditions: Schizophrenia
Interventions: Lurasidone, Quetiapine XR, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 29
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 23 more

Conditions: Major Depression
Interventions: quetiapine (Seroquel XR); Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Depressive Disorder, Major
Interventions: JNJ-42847922, Placebo Matching to JNJ-42847922, Quetiapine XR, Placebo Matching to Quetiapine XR, Selective Serotonin Reuptake Inhibitor (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor (SNRI); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Rogers, Arkansas + 41 more

Conditions: Bipolar Depression
Interventions: quetiapine (Seroquel) XR, placebo, pramipexole dihydrochloride; Drug
Lead sponsor: Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: San Diego, California • Kirkland, Washington

Conditions: Major Depressive Disorder, Generalized Anxiety Disorder
Interventions: Quetiapine XR, Placebo; Drug
Lead sponsor: Keming Gao; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Generalized Anxiety Disorder, Seroquel XR
Interventions: Seroquel XR; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day); Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 21 Years to 60 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Schizophrenia
Interventions: SEP363856, quetiapine XR; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 18
States / cities: Cerritos, California • Oakland, California • Oceanside, California + 15 more

Conditions: Depression, Healthy
Interventions: Quetiapine; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Panic Disorder
Interventions: quetiapine XR, placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder

Generalized Anxiety Disorder Adjunct Study

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Brain Imaging of Quetiapine Response in Anxious Depression

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

Generalized Anxiety and Seroquel

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Quetiapine in Melancholic Depression

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients